Study for pancreatic cancer using a biopsy-confirmed treatment approach
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial is for people with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) confirmed by biopsy. It tests a new treatment strategy after the cancer is diagnosed and considers people who haven’t had certain chemotherapy yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your pancreatic cancer diagnosis must be confirmed by biopsy (a tissue sample)
- Your CT scan must match pancreatic cancer
- You must not have had chemotherapy before, or you must have had it at least 2 months ago for pancreatic cancer
- You should be able to do daily activities with limited help (ECOG performance status 0–2)
- You must be able to give informed consent and have a permanent address and phone number
- You must be age 18 or older and not be pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study looks at how your body's chemistry, immune system, and gut bacteria interact during treatment for advanced pancreatic cancer that cannot be removed by surgery. Researchers will collect blood and stool samples to analyze these factors, hoping to better understand responses to therapy.
This trial tests a combination of endoscopic ultrasound-guided heat ablation (RFA) and the immunotherapy drug pembrolizumab for people with locally advanced or metastatic pancreatic cancer that cannot be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This study tests how safe and effective endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is for treating pancreatic growths that might become cancer or already are cancer. It is for people who are already scheduled to have this procedure as part of their care.
This early-phase trial is testing a new endoscopic (from inside the stomach) approach for pancreatic ductal adenocarcinoma that is locally advanced and cannot be removed with surgery. It may help some people who have already tried first chemotherapy and still have a tumor confined to the pancreas area (no spread).
This study uses small pancreatic cancer samples grown in the lab to understand which treatments may work best for people with pancreatic cancer. It may help researchers better “profile” tumors so standard care can be matched to the most effective options.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.